MSD appoints senior team to head up new biologics plant in Swords
Pharmaceutical giant MSD has appointed a new leadership team for MSD Biotech, Dublin a new biologics facility in Swords.
The new site will be led by Michael Flanagan, a biopharma operations director with over 25 years' experience, most recently as director of manufacturing with Bristol-Myers Squibb.
MSD Biotech, Dublin is expected to create 350 jobs. The facility, which is due to start production in 2021, will play a key role in the manufacture of MSD's biologics-based medicines, including in the area of immuno-oncology.
MSD currently employs over 1,800 people across four sites in Ireland - in Carlow, Cork, Dublin and Tipperary.
Its extensive Irish operations, encompassing manufacturing, commercial and marketing facilities, had a turnover of €4.7bn in 2016.
MSD has a strong legacy in Ireland that stretches back over the last 50 years, and has seen the company invest over $2.5bn in expanding and developing its facilities here.
The company provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immuno-oncology, infectious diseases and vaccines.
The Swords plant will make a drug substance called Keytruda, also known as Pembrolizumab. The facility will manufacture mammalian cell culture-based protein therapeutics.
Keytruda is currently manufactured by MSD in the Netherlands and at contract manufacturing sites in Germany and the United States.
MSD said the new Swords facility will bring the ability to manufacture "life-changing and life-saving medicines to patients worldwide".
MSD has had a presence on the north Dublin site since 1990.
Sunday Indo Business